MedPath

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Phase 3
Terminated
Conditions
Type 2 Diabetes Mellitus
Interventions
Registration Number
NCT00998686
Lead Sponsor
Phenomix
Brief Summary

The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
650
Inclusion Criteria
  • Completion of all required visits of a qualifying Phase 3 core protocol
  • Current treatment of Type 2 diabetes mellitus as in PHX1149-PROT302
Exclusion Criteria
  • Any condition, disease, disorder or clinically relevant laboratory abnormality which, in the opinion of the investigator, would jeopardize the patient's appropriate participation in this study or obscure the effects of treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sitagliptinsitagliptin-
dutogliptin/PHX1149Tdutogliptin-
Primary Outcome Measures
NameTimeMethod
To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG52 weeks
Secondary Outcome Measures
NameTimeMethod
To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose52 weeks

Trial Locations

Locations (43)

Phenomix Investigational Site 208

🇨🇿

Praha 10, Czech Republic

Phenomix Investigational Site 300

🇵🇱

Gdansk, Poland

Phenomix Investigational Site 306

🇵🇱

Pulawy, Poland

Phenomix Investigational Site 305

🇵🇱

Warszawa, Poland

Phenomix Investigational Site 706

🇮🇳

Indore, Madhya Pradesh, India

Phenomix Investigational Site 138

🇺🇸

Biloxi, Mississippi, United States

Phenomix Investigational Site 601

🇵🇪

Ica, Peru

Phenomix Investigational Site 604

🇵🇪

Lima, Peru

Phenomix Investigational Site 707

🇮🇳

Shastrinagar, Jaipur, India

Phenomix Investigational Site 110

🇺🇸

Trenton, New Jersey, United States

Phenomix Investigational Site 701

🇮🇳

Bangalore, Karnataka, India

Phenomix Investigational Site 112

🇺🇸

Greenville, South Carolina, United States

Phenomix Investigational Site 402

🇦🇷

Buenos Aires, Argentina

Phenomix Investigational Site 607

🇵🇪

Arequipa, Peru

Phenomix Investigational Site 103

🇺🇸

Long Beach, California, United States

Phenomix Investigational Site 143

🇺🇸

Coral Gables, Florida, United States

Phenomix Investigational Site 136

🇺🇸

Brockton, Massachusetts, United States

Phenomix Investigational Site 309

🇵🇱

Karkow, Poland

Phenomix Investigational Site 303

🇵🇱

Katowice, Poland

Phenomix Investigational Site 705

🇮🇳

Trivandrum, Kerala, India

Phenomix Investigational Site 302

🇵🇱

Wroclaw, Poland

Phenomix Investigational Site 610

🇵🇪

Lima, Peru

Phenomix Investigational Site 408

🇦🇷

Buenos Aires, Argentina

Phenomix Investigational Site 209

🇨🇿

Praha 4 Chodov, Czech Republic

Phenomix Investigational Site 410

🇦🇷

Mendoza, Argentina

Phenomix Investigational Site 207

🇨🇿

Unicov, Czech Republic

Phenomix Investigational Site 105

🇺🇸

Anaheim, California, United States

Phenomix Investigational Site 121

🇺🇸

Tempe, Arizona, United States

Phenomix Investigational Site 137

🇺🇸

Tempe, Arizona, United States

Phenomix Investigational Site 106

🇺🇸

Los Angeles, California, United States

Phenomix Investigational Site 142

🇺🇸

Hialeah, Florida, United States

Phenomix Investigational Site 133

🇺🇸

Kissimmee, Florida, United States

Phenomix Investigational Site 101

🇺🇸

Honolulu, Hawaii, United States

Phenomix Investigational Site 135

🇺🇸

Chicago, Illinois, United States

Phenomix Investigational Site 124

🇺🇸

Indianapolis, Indiana, United States

Phenomix Investigational Site 122

🇺🇸

Las Vegas, Nevada, United States

Phenomix Investigational Site 140

🇺🇸

Las Vegas, Nevada, United States

Phenomix Investigational Site 116

🇺🇸

Albuquerque, New Mexico, United States

Phenomix Investigational Site 107

🇺🇸

Winston-Salem, North Carolina, United States

Phenomix Investigational Site 102

🇺🇸

Dallas, Texas, United States

Phenomix Investigational Site 104

🇺🇸

San Antonio, Texas, United States

Phenomix Investigational Site 100

🇺🇸

Kenosha, Wisconsin, United States

Phenomix Investigational Site 711

🇮🇳

Mumbai, Maharashtra, India

© Copyright 2025. All Rights Reserved by MedPath